Current Standards for Organ Preservation in Locoregionally Advanced Non-nasopharyngeal Head and Neck Cancer and Evolving Strategies for Favorable-Risk and Platinum-Ineligible Populations

Wu, Susan; Yom, Sue S.

doi:10.1007/s11864-019-0688-4

Cited by 5 publications

(6 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Concerning definitive/curative settings, radiation with high-dose cisplatin remains the standard of care in HPV+ OPSCC, since two randomized controlled trials (DeEscalate and RTOG 1016) have demonstrated that standard therapy with concomitant high-dose cisplatin effects a better cure rate than the less toxic cetuximab [ 62 , 63 ]. Current studies are evaluating the possibility of replacing cisplatin with checkpoint inhibitors as a de-intensification strategy (e.g., HN5 [ 64 ] and REACH [ 65 ]).…”

Section: Therapeutic Vaccinesmentioning

confidence: 99%

Therapeutic Vaccines for HPV-Associated Oropharyngeal and Cervical Cancer: The Next De-Intensification Strategy?

Morand

Cardona

Cruz

et al. 2022

IJMS

View full text Add to dashboard Cite

The rise in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC) has prompted a quest for further understanding of the role of high-risk HPV in tumor initiation and progression. Patients with HPV-positive OPSCC (HPV+ OPSCC) have better prognoses than their HPV-negative counterparts; however, current therapeutic strategies for HPV+ OPSCC are overly aggressive and leave patients with life-long sequalae and poor quality of life. This highlights a need for customized treatment. Several clinical trials of treatment de-intensification to reduce acute and late toxicity without compromising efficacy have been conducted. This article reviews the differences and similarities in the pathogenesis and progression of HPV-related OPSCC compared to cervical cancer, with emphasis on the role of prophylactic and therapeutic vaccines as a potential de-intensification treatment strategy. Overall, the future development of novel and effective therapeutic agents for HPV-associated head and neck tumors promises to meet the challenges posed by this growing epidemic.

show abstract

Section: Therapeutic Vaccinesmentioning

confidence: 99%

Therapeutic Vaccines for HPV-Associated Oropharyngeal and Cervical Cancer: The Next De-Intensification Strategy?

Morand

Cardona

Cruz

et al. 2022

IJMS

View full text Add to dashboard Cite

show abstract

“…Novels agents such as PDL1 inhibitors or targeted therapy are potentially less toxic than traditional cisplatin HN5 [31] REACH [32] Radiotherapy dose reduction…”

Section: Switch To Less Toxic Concomitant Chemotherapymentioning

confidence: 99%

Historical Perspective: How the Discovery of HPV Virus Led to the Utilization of a Robot

Morand

Sultanem

Mascarella

et al. 2022

Front. Oral. Health

View full text Add to dashboard Cite

The treatment of oropharyngeal cancer has undergone many paradigms shifts in recent decades. First considered a surgical disease, improvements in radiotherapy led to its popularization in the 1990s. Subsequently, the discovery of the human papillomavirus (HPV) in the pathogenesis of oropharyngeal cancer, as well as the increase in HPV-associated oropharynx cancer incidence, have prompted a reevaluation of its management. Its sensitivity to standard treatment with a favorable prognosis compared to non HPV-associated oropharyngeal cancer led to a focus on minimizing treatment toxicity. Advances in radiation and surgical techniques, including the use of transoral robotic surgery, gave the rationale to ongoing de-escalation clinical trials in HPV-associated oropharynx cancer.

show abstract

“…The mainstay of treatment for all locoregionally advanced head and neck SCCs is either surgery followed by aRT or upfront CRT, reserving surgery as salvage therapy [ 44 ]. In primary paranasal sinus tumors, complete resection of the tumor should be first attempted.…”

Section: Nasal Cavity/paranasal Sinusmentioning

confidence: 99%

An Updated Review on Head and Neck Cancer Treatment with Radiation Therapy

Anderson

Ebadi

et al. 2021

Cancers

101

View full text Add to dashboard Cite

The complexity of head and neck cancers (HNC) mandates a multidisciplinary approach and radiation therapy (RT) plays a critical role in the optimal management of patients with HNC, either as frontline or adjuvant treatment postoperatively. The advent of both definitive and post-operative RT has significantly improved the outcomes of patients with HNC. Herein, we discuss the role of postoperative RT in different subtypes of HNC, its side effects, and the importance of surveillance. The treatment regions discussed in this paper are the oral cavity, nasopharynx, paranasal sinus cavity, oropharynx, larynx and hypopharynx. Multiple studies that demonstrate the importance of definitive and/or postoperative RT, which led to an improved outlook of survival for HNC patients will be discussed.

show abstract

Current Standards for Organ Preservation in Locoregionally Advanced Non-nasopharyngeal Head and Neck Cancer and Evolving Strategies for Favorable-Risk and Platinum-Ineligible Populations

Cited by 5 publications

References 72 publications

Therapeutic Vaccines for HPV-Associated Oropharyngeal and Cervical Cancer: The Next De-Intensification Strategy?

Therapeutic Vaccines for HPV-Associated Oropharyngeal and Cervical Cancer: The Next De-Intensification Strategy?

Historical Perspective: How the Discovery of HPV Virus Led to the Utilization of a Robot

An Updated Review on Head and Neck Cancer Treatment with Radiation Therapy

Contact Info

Product

Resources

About